Future of Healthcare

Quipt Home Medical Announces Supply Contract with Cardinal Health Further Expanding Continuum of Care

Quipt Home

Quipt Home Medical Corp. a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce the execution of a contract with Cardinal Health at-Home, a business unit of Cardinal Health, Inc. wherein Quipt has agreed to offer to sell, and Cardinal has agreed to supply and distribute, disposable medical supplies nationwide. Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities.  

The execution of this contract with Cardinal Health for the supply of disposable medical supplies is an important milestone for Quipt, and we are thrilled to form this alliance during a period of significant growth. Cardinal will service our entire operating footprint, consisting of 94 locations across the country aimed at increasing distribution channels while decreasing costs. Furthermore, this contract will provide us the ability to expand our continuum of care, produce meaningful cross selling opportunities and allow us to further leverage the national insurance contract recently announced. This contract with Cardinal will also assist us in expanding our presence in the states we serve giving us additional verticals to go after. Additionally, any new acquisitions, will benefit from being able to immediately leverage the contract at new locations across the country, providing further synergies with the expectation this contract will give us stronger buying power for disposable medical supplies. The contract with Cardinal, recent new national insurance contract, and deep acquisition pipeline have us extremely excited about the remainder of 2022 and beyond.” 

 Greg Crawford, Chairman and CEO of Quipt

ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.

ABOUT CARDINAL HEALTH
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Cardinal Health at-Home provides Home Medical Equipment and Home Health and Hospice teams with comprehensive solutions to better support their patients in the home.

Spotlight

Other News
Healthcare Analytics

Weave Introduces AI-Driven Voicemail Transcriptions for Healthcare Providers

Business Wire | October 31, 2023

Weave a leading all-in-one experience platform for small and medium-sized healthcare practices, today announces the addition of AI-driven voicemail transcriptions to its platform. Now available to Weave’s 27,000+ customers, Voicemail Transcription automatically transcribes voicemails from patients allowing for efficient, visible, and private reading experiences. With this update, users will now see the voicemail transcription when they click on the Voicemail tab within their Desktop Application or within the mobile app, improving overall user experience by making it faster to consume messages without having to listen to the audio, which can often be difficult in busy settings. said Branden Neish, Chief Product and Technology Officer at Weave. AI has exploded in popularity over the past year, and we’re taking steps to ensure Weave is delivering state of the art offerings that empower our customers to enhance patient experiences and deliver top of the line care. AI will only continue to grow in popularity and daily use, which will have a transformative impact on the future of the healthcare industry. Weave customers that have already implemented AI into their practices claim they save an average of an hour a day with the technology. [Source:Business Wire] In a new customer and consumer report conducted by Weave, the company found that patients are accepting of AI in healthcare settings and they see it leading to enhanced care and patient experiences. In fact, the majority of consumers (65%) are open to providers using AI tools in their practices. The report also found that consumers and providers are aligned with how they think AI will impact the healthcare industry, with two in three consumers (67%) and 3 in 4 (75%) healthcare providers believing that AI is likely to become a prevalent tool in healthcare. "Artificial Intelligence is the catalyst for a new era in healthcare,” says Dr. Matt Nejad, DDS of Beverly Hills, CA. “Weave's AI-enabled voicemail transcripts are a leap in this direction, providing automation and actionable insights that empower providers to focus on what truly matters: patient care." This announcement follows months of AI-driven activity from Weave to enhance features that allow healthcare providers to deliver quality care and improve patient experiences, including Email Assistant and Response Assistant. About Weave Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.

Read More

Healthcare Analytics

WELL Health Launches 'WELL AI Decision Support' powered by HEALWELL AI; Empowering Healthcare Providers with Next Generation Decision Support Systems

PR Newswire | October 19, 2023

WELL Health Technologies Corp. a digital health company focused on tech-enabling healthcare providers, and its investee company, HEALWELL AI are pleased to announce the launch of "WELL AI Decision Support", a groundbreaking new service for healthcare providers. This partnership is the first major collaborative initiative between the two companies since the announcement of the Strategic Alliance Agreement on October 3, 2023. Both companies view this as the beginning of a long-term, mutually beneficial partnership, with a shared vision and commitment to ongoing innovation. Hamed Shahbazi, Founder and CEO of WELL commented, "We firmly believe the physician experience of the not-too-distant future will involve a number of safe, secure and helpful digital diagnostic tools that will better support healthcare providers in detecting acute and chronic diseases earlier. The launch of 'WELL AI Decision Support' perfectly aligns with our core strategy to empower healthcare providers with transformative technology, enhancing their capacity to improve patient outcomes and promote preventative health." Dr. Michael Frankel, Chief Medical Officer of WELL, added, "The arrival of 'WELL AI Decision Support' marks more than just technological advancement; it's a watershed moment in our pursuit of superior patient care. By harnessing AI's potential, we are equipping healthcare professionals with tools that refine and elevate their practice. Each patient deserves individualized attention and precision in care, and this module is a step forward in realizing that vision." Dr. Alexander Dobranowski, CEO of HEALWELL AI, said. Our partnership with WELL is a strategic imperative in healthcare. The alignment between HEALWELL's pioneering data science and WELL's expansive clinical network underscores the strength of our collaboration. Together, with WELL's robust healthcare software solutions, we are creating a synergy poised to redefine healthcare standards. This partnership amplifies our combined commitment to leveraging data science for healthcare applications, ultimately benefiting patients and healthcare providers alike. [Source: PR Newswire] The 'WELL AI Decision Support' module is a groundbreaking solution that bridges a critical gap in healthcare diagnostics and patient care, heralding a new era of precision in healthcare delivery. WELL AI Decision Support leverages artificial intelligence (AI) technologies to enable the earlier diagnosis, treatment and improved quality of life for the patient. The technology behind WELL AI Decision Support has been meticulously developed by HEALWELL, in close collaboration with dedicated physicians, leading researchers, data privacy professionals, pharmaceutical companies, and other domain experts. This rigorous process of development and refinement has led to its validation in both Canadian and U.S. healthcare systems. WELL AI Decision Support is also a highly modular service that will be expanded with time. Initially, the service enables healthcare providers to accurately identify over 110 complex or rare diseases often overlooked by traditional methods, providing hope to thousands of patients across Canada. 'WELL AI Decision Support' is the second significant product release under the WELLHealth.ai program, following the successful "WELL AI Voice" module, and further exemplifies WELL's unwavering commitment and leadership in delivering effective AI solutions in healthcare. WELL AI Decision Support is featured on apps.health, WELL's premium digital marketplace for EMR tools and applications. Rare and complex diseases affect over 300 million patients worldwide, and in Canada, 1 in 12 individuals lives with a rare disorder. What's even more alarming is the substantial number of people who remain undiagnosed and unaware of their underlying conditions. For those who do exhibit symptoms, the journey to a correct diagnosis is an arduous one. On average, they consult 8 physicians, endure 2-3 misdiagnoses over a span of 4.8yrs before receiving an accurate diagnosis. This partnership represents a significant win for HEALWELL, granting expansive channel access to healthcare providers. The launch of 'WELL AI Decision Support' module underscores the trust and validation of HEALWELL's expertise within the industry. Both WELL and HEALWELL plan to continue to collaborate to combine their expertise and capabilities for more groundbreaking developments in the future. About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 31,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 148 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF". About HEALWELL AI Inc. HEALWELL AI is a health care technology company focused on AI and data science for preventive care. Its mission is to improve health care and save lives through early identification and detection of disease. As a physician-led organization with a proven management team of experienced executives, HEALWELL AI is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the company's road map.

Read More

Health Technology

Verily Introduces Viewpoint Workbench to Boost Biomedical Research

Verily | October 09, 2023

Verily, an Alphabet subsidiary focused on precision health technology, has unveiled Viewpoint Workbench, a new enterprise-grade platform created to consolidate multimodal data and expedite biomedical research. Workbench offers a secure collaborative setting for data generators, researchers, and biopharmaceutical organizations to oversee and analyze their data. This platform is a component of Verily Viewpoint, a comprehensive suite of solutions that enable the generation of evidence necessary for expediting the availability of safe and effective therapies to individuals in need. Scott Burke, Chief Technology Officer, Verily, said, Researchers are gathering more data of more types than ever, but it is challenging to effectively store, access, and analyze it while complying with data governance mandates. [Source – Business Wire] Scott Burke added that Workbench can adapt to any organization and helps researchers use data to advance scientific understanding. Workbench integrates technology and optimal methodologies honed over several years of constructing data infrastructure for extensive research undertakings, including National Institutes of Health's All of Us Research Program, Accelerating Medicines Partnership Parkinson's Disease (AMP PD) program, and Project Baseline Health Study. Dr. James Lu, MD, Ph.D., CEO and Co-Founder of Helix, emphasized the importance of a platform that can effectively integrate multiple data layers to advance their work significantly. He expressed enthusiasm about integrating Verily's Workbench, which will facilitate collaborative research and yield more informed insights. Additionally, Manish Raisinghani, MBBS, Ph.D., President and CEO of Target ALS, stressed the need to maintain momentum in accelerating ALS drug discovery. He mentioned that Workbench aligns with their ambitious initiative to create a comprehensive biosample and dataset collection for ALS and to provide unrestricted access to scientists worldwide, thus promoting progress in their research endeavors. Workbench enables secure collaboration among data generators, research sponsors, and biomedical researchers. Users can analyze multimodal data, ensure data governance through access control, and engage with a growing network of researchers to advance scientific progress and promote reproducible research. About Verily Verily, an Alphabet health technology company, specializes in research, healthcare delivery, and health financing. Its mission is to advance precision health and promote healthier lives by operating at the intersection of technology, data science, and healthcare. The company develops tools to accelerate evidence generation, creates products for more personalized care, and introduces approaches to enhance cost predictability.

Read More

Health Technology, Digital Healthcare

Aspect Imaging to bring Improvements in NICUs for Vizient

Aspect Imaging | September 25, 2023

Aspect Imaging, a global leader in MRI systems for neonatal patients, has been awarded an Innovative Technology contract by Vizient, the nation's largest provider -driven healthcare performance improvement company. This contract recognizes the unique qualities of Aspect Imaging's Embrace Point of Care Neonatal MRI System and its potential to bring improvements to the healthcare industry. The Embrace Point of Care Neonatal MRI System is designed specifically for the imaging needs of prematureand newborn infants, making it a critical tool in neonatal intensive care units (NICUs). The Embrace is the world's first FDA-cleared and CE-approved MRI system for neonatal patients. It is designed to be placed directly within NICUs, overcoming the size and risk limitations associated with adult MRI scanners. The system includes features such as a temperature-controlled patient bed and a Whisper Quiet sound profile to meet the specific care needs of neonatal patients. This technology enables safer and more accessible MRI imaging for fragile neonatal patients and provides critical information to the clinical care team. Chief Commercial Officer at Aspect Imaging, Wendy Slatery, stated, It is an honor to have the Embrace recognized by the clinical experts at Vizient, as an Innovative Technology, and an exciting opportunity to bring valuable solutions to Vizient customers. We are looking forward to working with Vizient members seeking to expand and elevate neurocritical care of the smallest patients while reducing patient risks and staff time associated with transporting newborns to a traditional MRI. The Embrace MRI gives the neonatal medical team access to information from the life’s first hours and throughout the patient’s time in the NICU, on which critical care decisions will be based. [Source: Business Wire] Vizient's provider customer-led councils recommended the Embrace system for an Innovative Technology contract after evaluating its potential to enhance clinical care, patient safety, and healthcare worker safety, or improve business operations in healthcare organizations. The recognition and award of this contract highlight the potential of the Embrace Point of Care Neonatal MRI System to improve neurocritical care for the smallest patients while reducing risks associated with transporting newborns to traditional MRI facilities. About Aspect Imaging Aspect Imaging, a pioneering force in the field, stands as the global frontrunner in crafting and advancing compact MR imaging systems tailored for both research and clinical use. Their groundbreaking technology centers on compact, high-performance permanent magnets, introducing transformative MRI solutions to tackle unmet requirements in research and medical contexts. These innovations ensure the delivery of the finest quality images, whether at the benchtop or in point-of-care scenarios.

Read More